基于Bone-RADS MRI算法评估脊柱病变的表现与可重复性
本研究回顾性纳入282个脊柱MRI病变,评估Bone-RADS MRI算法的诊断效能与观察者间一致性。结果显示Bone-RADS 1分对恶性病变的阴性预测值为100%,2/3分病变恶性率低,纳入临床排除标准后降至0%。观察者间一致性为中等(Cohen's kappa=0.60),提示在该解剖部位应用需谨慎。
要点
- Bone-RADS 1分脊柱病变恶性阴性预测值达100%,可安全避免不必要的随访。
- Bone-RADS 2/3分脊柱病变恶性率仅3.4%,纳入临床排除标准后降至0%。
- 该算法观察者间一致性仅为中等(κ=0.60),阅片时需注意评分分歧。
核心结论
- Bone-RADS 1分对脊柱病变具有极好的阴性预测值(100%),可有效排除恶性。
- Bone-RADS 2/3分病变恶性率低,纳入排除性临床标准后恶性率降为0%。
- Bone-RADS MRI算法在本队列中观察者间一致性为中等(κ=0.60),在脊柱部位应用需谨慎。
研究设计与样本
- 回顾性研究,对放射报告关键词「indeterminate」搜索所得的538例脊柱MRI检查进行筛选,最终282个椎体病变符合纳入标准。
- 两名经CAQ认证的神经放射科医生独立阅片并采用Bone-RADS评分,分歧评分经协商达成共识。
- 排除标准为MRI方案缺少T1WI或T2WI序列,或已知椎体转移病史。
- 以PACS和EMR回顾为参考,将病变分为稳定、随访不完全、典型良性或退行性、恶性或无随访类别。
关键影像表现/征象
- Bone-RADS稳定定义为≥24个月的随访无变化,2-24个月无变化视为随访不完全,<2个月影像视为无随访。
- CT随访超过2年显示无变化或骨质正常表现的病变也被定义为稳定。
- 本队列中66%的患者无已知恶性肿瘤病史,新诊断骨转移4例,浆细胞瘤2例。
- 60%的病变有后续诊断或≥2个月的影像随访。
诊断标准与关键数值
- Bone-RADS 1分阴性预测值为100%(95%CI 94.7-100%,n=46)。
- Bone-RADS 2/3分不确定病变阳性预测值为3.4%(95%CI 1.2-8.0%,n=116)。
- 纳入Bone-RADS临床排除标准后,不确定病变阳性预测值降至0%(95%CI 0-3.0%,n=81)。
- 观察者间一致性Cohen's kappa为0.60。
临床应用与阅片要点
- Bone-RADS 1分脊柱病变可安全归类为良性,无需常规建议随访。
- 本研究中80%原始放射报告对Bone-RADS 1分病变建议了随访,存在过度随访可能。
- 由于脊柱良性病变与转移性病变均高发而原发性骨肿瘤相对少见,应用Bone-RADS时需警惕算法局限性。
- 鉴于观察者间一致性仅为中等,报告Bone-RADS评分时应注意评分分歧的可能性,必要时通过共识降低误差。
局限性
- 本研究为回顾性设计,可能存在选择偏倚和信息偏倚。
- 观察者间一致性仅为中等(κ=0.60),提示该算法在脊柱部位的可重复性有限。
- Bone-RADS在设计时主要针对四肢骨肿瘤,在脊柱椎体这一原发骨肿瘤少见而转移和良性病变高发区域适用性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the inter-rater reliability and accuracy of the SSR Bone-RADS MRI algorithm for challenging osseous vertebral lesions.
MATERIALS AND METHODS: We retrospectively reviewed 538 MRI exams with vertebral lesions described in the radiology reports resulting from a keyword search of "indeterminate." Studies were excluded if protocols lacked T1WI or T2WI or if there was known history of vertebral metastases. Based on PACS and EMR review, lesions were categorized as stable, incomplete follow-up, typically benign or degenerative, malignant or no follow-up. Per Bone-RADS, stability required follow-up at ≥24 months. No change at 2-24 months was considered incomplete follow-up and imaging at <2 months was considered no follow-up. Lesions were also defined as stable if CT imaging >2 years later showed no change or normal appearing bone. Malignancy status was divided into (1) none known, (2) no known metastatic disease and (3) known metastatic disease. Two CAQ-certified neuroradiologists independently reviewed the images and scored each lesion using Bone-RADS. They did not incorporate Bone-RADS clinical criteria and cases with multiple lesions were not excluded. Discrepant scores were reviewed for consensus. Predictive values and inter-rater reliability were calculated.
RESULTS: 282 vertebral lesions met inclusion criteria. 60% had subsequent diagnosis or imaging follow-up of ≥2 months. 66% of these patients had no reported malignancy history. There were four cases of newly diagnosed bone metastases and two cases of plasmacytoma. The negative predictive value (NPV) of Bone-RADS 1 was 100% (95% CI [94.7-100%], n = 46). Positive predictive value for indeterminate lesions was 3.4% (95% CI [1.2-8.0%], n = 116); when Bone-RADS clinical criteria were applied this decreased to 0% (95% CI [0-3.0%], n = 81). Cohen's kappa test for inter-reader reliability was 0.60. Of cases scored as Bone-RADS 1, 80% of original radiologist reports had advised follow-up.
CONCLUSION: A Bone-RADS 1 score showed excellent NPV for vertebral lesions. Lesions scored as 2/3 had low malignancy rate which decreased to 0% when exclusionary clinical criteria were incorporated. The Bone-RADS MRI algorithm had moderate inter-reader reliability on our cohort. Given intermediate inter-reader reliability and the high prevalence of both benign and metastatic vertebral lesions relative to primary bone tumors, radiologists should be cautious when applying Bone-RADS to this anatomic region. A vertebral specific algorithm would be helpful.
引用
- Barkovich, Mehan, Buch, et al. Performance and Reproducibility of Bone-RADS MRI Algorithm for Vertebral Lesions. AJNR Am J Neuroradiol. 2026. PMID: 42557020. doi:10.3174/ajnr.A9571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。